Roche entered an agreement with Zymeworks worth up to $813 million for ZW209, a trispecific T-cell engager targeting DLL3. Roche will pay $55 million upfront and additional payments tied to Phase Ib initiation, with further milestones and tiered royalties dependent on development and sales outcomes. Zymeworks will continue work on the monotherapy Phase Ia alongside Roche, while Roche assumes global development and commercialization. The structure reflects a common strategy in multispecific oncology: large-pharma rights in exchange for risk-sharing and milestone-based upside. The transaction highlights intensifying competition around DLL3-directed T-cell engaging platforms, including interest from Roche in differentiating depth and durability of immune-mediated responses.